Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CP-31398 |
Synonyms | |
Therapy Description |
CP-31398 stabilizes wild-type Tp53 conformation, and activates Tp53 activity in cells with wild-type or mutant Tp53, potentially resulting in increased tumor cell death (PMID: 14614447, PMID: 32633026, PMID: 32468177). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CP-31398 | CP31398|CP 31398 | p53 Activator 11 | CP-31398 stabilizes wild-type Tp53 conformation, and activates Tp53 activity in cells with wild-type or mutant Tp53, potentially resulting in increased tumor cell death (PMID: 14614447, PMID: 32633026, PMID: 32468177). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R249S | hepatocellular carcinoma | sensitive | CP-31398 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460). | 26250460 |
TP53 Y220C | hepatocellular carcinoma | sensitive | CP-31398 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460). | 26250460 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|